AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT102.61-1.46 (-1.40%) ▼|ACN238.96+2.03 (+0.86%) ▲|ADBE255.26+8.17 (+3.30%) ▲|AMAT406.46-6.65 (-1.61%) ▼|AMD542.18+4.13 (+0.77%) ▲|AMGN434.83+9.89 (+2.33%) ▲|AMT184.65+1.62 (+0.88%) ▲|AMZN263.10+0.65 (+0.25%) ▲|AVGO335.28+0.69 (+0.21%) ▲|AXP319.86+3.45 (+1.09%) ▲|BA191.31-0.12 (-0.06%) ▼|BAC50.80+0.41 (+0.81%) ▲|BKNG164.47+1.87 (+1.15%) ▲|BLK1,129.24+4.64 (+0.41%) ▲|BMY61.60+2.77 (+4.71%) ▲|BNY144.36+1.92 (+1.35%) ▲|BRK-B537.93+5.70 (+1.07%) ▲|C122.39+0.70 (+0.58%) ▲|CAT726.45+0.66 (+0.09%) ▲|CL94.02+1.16 (+1.24%) ▲|CMCSA22.21+0.31 (+1.39%) ▲|COF201.93+2.10 (+1.05%) ▲|COP145.84+0.60 (+0.41%) ▲|COST995.38-0.15 (-0.02%) ▼|CRM242.07-0.39 (-0.16%) ▼|CSCO106.63+0.13 (+0.12%) ▲|CVS94.11+1.43 (+1.54%) ▲|CVX224.76+0.39 (+0.17%) ▲|DE636.27+9.27 (+1.48%) ▲|DHR225.45+1.02 (+0.45%) ▲|DIS111.60+2.01 (+1.83%) ▲|DUK121.25+1.98 (+1.66%) ▲|EMR159.79-0.76 (-0.47%) ▼|FDX300.57+6.79 (+2.31%) ▲|GD344.41+2.98 (+0.87%) ▲|GE299.48-11.80 (-3.79%) ▼|GEV896.82-11.62 (-1.28%) ▼|GILD156.32+3.25 (+2.12%) ▲|GM75.90-6.86 (-8.28%) ▼|GOOG336.78-3.38 (-0.99%) ▼|GOOGL340.69-3.49 (-1.01%) ▼|GS885.74+9.96 (+1.14%) ▲|HD315.78+5.90 (+1.90%) ▲|HON212.18+2.20 (+1.05%) ▲|IBM240.33+3.94 (+1.67%) ▲|INTC92.54+0.51 (+0.55%) ▲|INTU336.52+10.90 (+3.35%) ▲|ISRG438.78+5.60 (+1.29%) ▲|JNJ259.72+5.93 (+2.34%) ▲|JPM335.76+2.23 (+0.67%) ▲|KO92.75-0.68 (-0.72%) ▼|LIN499.70-3.75 (-0.74%) ▼|LLY1,292.02+51.68 (+4.17%) ▲|LMT549.29+1.06 (+0.19%) ▲|LOW199.33+3.41 (+1.74%) ▲|LRCX265.14-7.06 (-2.59%) ▼|MA622.00+5.60 (+0.91%) ▲|MCD245.62+2.95 (+1.21%) ▲|MDLZ63.87+0.53 (+0.83%) ▲|MDT94.57+1.80 (+1.94%) ▲|META690.14-15.30 (-2.17%) ▼|MMM171.17+9.16 (+5.65%) ▲|MO74.43+0.34 (+0.46%) ▲|MRK148.25+4.62 (+3.22%) ▲|MS180.42+1.95 (+1.09%) ▲|MSFT532.48-1.04 (-0.19%) ▼|MU909.62+4.72 (+0.52%) ▲|NEE78.83+0.66 (+0.84%) ▲|NFLX69.29-0.56 (-0.80%) ▼|NKE37.95+0.74 (+1.98%) ▲|NOW149.61+4.25 (+2.92%) ▲|NVDA217.09+0.00 (+0.00%) ▲|ORCL131.78+2.19 (+1.69%) ▲|PEP134.26+0.69 (+0.52%) ▲|PFE30.24+0.80 (+2.70%) ▲|PG158.22+0.53 (+0.33%) ▲|PLTR195.76+1.61 (+0.83%) ▲|PM200.05-1.00 (-0.50%) ▼|QCOM176.25+2.72 (+1.57%) ▲|RTX191.57-0.55 (-0.28%) ▼|SBUX99.44+1.57 (+1.60%) ▲|SCHW90.69+1.11 (+1.24%) ▲|SO90.80+1.53 (+1.71%) ▲|SPG205.95+3.46 (+1.71%) ▲|T23.55+0.35 (+1.49%) ▲|TMO690.26+10.88 (+1.60%) ▲|TMUS157.96+1.87 (+1.20%) ▲|TSLA374.66+6.60 (+1.79%) ▲|TXN279.33+3.18 (+1.15%) ▲|UBER69.00-0.96 (-1.37%) ▼|UNH420.66+13.78 (+3.39%) ▲|UNP288.10+1.09 (+0.38%) ▲|UPS99.00+1.54 (+1.58%) ▲|USB58.91+1.06 (+1.83%) ▲|V407.29+4.37 (+1.08%) ▲|VZ44.56+0.41 (+0.92%) ▲|WFC81.64-0.17 (-0.20%) ▼|WMT118.35-0.35 (-0.29%) ▼|XOM177.16-1.12 (-0.63%) ▼|AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT102.61-1.46 (-1.40%) ▼|ACN238.96+2.03 (+0.86%) ▲|ADBE255.26+8.17 (+3.30%) ▲|AMAT406.46-6.65 (-1.61%) ▼|AMD542.18+4.13 (+0.77%) ▲|AMGN434.83+9.89 (+2.33%) ▲|AMT184.65+1.62 (+0.88%) ▲|AMZN263.10+0.65 (+0.25%) ▲|AVGO335.28+0.69 (+0.21%) ▲|AXP319.86+3.45 (+1.09%) ▲|BA191.31-0.12 (-0.06%) ▼|BAC50.80+0.41 (+0.81%) ▲|BKNG164.47+1.87 (+1.15%) ▲|BLK1,129.24+4.64 (+0.41%) ▲|BMY61.60+2.77 (+4.71%) ▲|BNY144.36+1.92 (+1.35%) ▲|BRK-B537.93+5.70 (+1.07%) ▲|C122.39+0.70 (+0.58%) ▲|CAT726.45+0.66 (+0.09%) ▲|CL94.02+1.16 (+1.24%) ▲|CMCSA22.21+0.31 (+1.39%) ▲|COF201.93+2.10 (+1.05%) ▲|COP145.84+0.60 (+0.41%) ▲|COST995.38-0.15 (-0.02%) ▼|CRM242.07-0.39 (-0.16%) ▼|CSCO106.63+0.13 (+0.12%) ▲|CVS94.11+1.43 (+1.54%) ▲|CVX224.76+0.39 (+0.17%) ▲|DE636.27+9.27 (+1.48%) ▲|DHR225.45+1.02 (+0.45%) ▲|DIS111.60+2.01 (+1.83%) ▲|DUK121.25+1.98 (+1.66%) ▲|EMR159.79-0.76 (-0.47%) ▼|FDX300.57+6.79 (+2.31%) ▲|GD344.41+2.98 (+0.87%) ▲|GE299.48-11.80 (-3.79%) ▼|GEV896.82-11.62 (-1.28%) ▼|GILD156.32+3.25 (+2.12%) ▲|GM75.90-6.86 (-8.28%) ▼|GOOG336.78-3.38 (-0.99%) ▼|GOOGL340.69-3.49 (-1.01%) ▼|GS885.74+9.96 (+1.14%) ▲|HD315.78+5.90 (+1.90%) ▲|HON212.18+2.20 (+1.05%) ▲|IBM240.33+3.94 (+1.67%) ▲|INTC92.54+0.51 (+0.55%) ▲|INTU336.52+10.90 (+3.35%) ▲|ISRG438.78+5.60 (+1.29%) ▲|JNJ259.72+5.93 (+2.34%) ▲|JPM335.76+2.23 (+0.67%) ▲|KO92.75-0.68 (-0.72%) ▼|LIN499.70-3.75 (-0.74%) ▼|LLY1,292.02+51.68 (+4.17%) ▲|LMT549.29+1.06 (+0.19%) ▲|LOW199.33+3.41 (+1.74%) ▲|LRCX265.14-7.06 (-2.59%) ▼|MA622.00+5.60 (+0.91%) ▲|MCD245.62+2.95 (+1.21%) ▲|MDLZ63.87+0.53 (+0.83%) ▲|MDT94.57+1.80 (+1.94%) ▲|META690.14-15.30 (-2.17%) ▼|MMM171.17+9.16 (+5.65%) ▲|MO74.43+0.34 (+0.46%) ▲|MRK148.25+4.62 (+3.22%) ▲|MS180.42+1.95 (+1.09%) ▲|MSFT532.48-1.04 (-0.19%) ▼|MU909.62+4.72 (+0.52%) ▲|NEE78.83+0.66 (+0.84%) ▲|NFLX69.29-0.56 (-0.80%) ▼|NKE37.95+0.74 (+1.98%) ▲|NOW149.61+4.25 (+2.92%) ▲|NVDA217.09+0.00 (+0.00%) ▲|ORCL131.78+2.19 (+1.69%) ▲|PEP134.26+0.69 (+0.52%) ▲|PFE30.24+0.80 (+2.70%) ▲|PG158.22+0.53 (+0.33%) ▲|PLTR195.76+1.61 (+0.83%) ▲|PM200.05-1.00 (-0.50%) ▼|QCOM176.25+2.72 (+1.57%) ▲|RTX191.57-0.55 (-0.28%) ▼|SBUX99.44+1.57 (+1.60%) ▲|SCHW90.69+1.11 (+1.24%) ▲|SO90.80+1.53 (+1.71%) ▲|SPG205.95+3.46 (+1.71%) ▲|T23.55+0.35 (+1.49%) ▲|TMO690.26+10.88 (+1.60%) ▲|TMUS157.96+1.87 (+1.20%) ▲|TSLA374.66+6.60 (+1.79%) ▲|TXN279.33+3.18 (+1.15%) ▲|UBER69.00-0.96 (-1.37%) ▼|UNH420.66+13.78 (+3.39%) ▲|UNP288.10+1.09 (+0.38%) ▲|UPS99.00+1.54 (+1.58%) ▲|USB58.91+1.06 (+1.83%) ▲|V407.29+4.37 (+1.08%) ▲|VZ44.56+0.41 (+0.92%) ▲|WFC81.64-0.17 (-0.20%) ▼|WMT118.35-0.35 (-0.29%) ▼|XOM177.16-1.12 (-0.63%) ▼|
20.2 C
New York
Tuesday, October 20, 2026

Tag: drug

newsFORsourcecompanycontentinformation1releasesmarket

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine...

Sterile ketamine products currently for sale in the United States contain benzethonium chloride, a preservative with known toxicity that is not Generally Recognized as...

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST)

HKBU leads the development of multifunctional nanorobots for precise and effective pollutant degradation and bacterial removal

HONG KONG, Aug. 4, 2025 /PRNewswire/ -- A collaborative research team led by Hong Kong Baptist University (HKBU) has developed a multifunctional nanorobot equipped...

HKBU leads the development of multifunctional nanorobots for precise and effective pollutant degradation and bacterial removal

HONG KONG, Aug. 4, 2025 /PRNewswire/ -- A collaborative research team led by Hong Kong Baptist University (HKBU) has developed a multifunctional nanorobot equipped...

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India,...

Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

BEIJING, Aug. 3, 2025 /PRNewswire/ -- Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient...

Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

BEIJING, Aug. 4, 2025 /PRNewswire/ -- Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing...

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling

Certara today announced that the European Medicines Agency has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India,...

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently...

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India,...

ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR

NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline.

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in...

Pilly Labs Aligns with 2025 Demand for the Best Nutritional Gummies Supporting Whole Body Wellness

In a year defined by holistic health trends, anti-inflammatory nutrition stacks, and consumer-led demand for clean-label routines, Pilly Labs is emerging as a go-to gummy supplement brand for wellness seekers prioritizing transparency and convenience. With turmeric, mushroom extracts, and collagen continuing to dominate 2025’s ingredient interest charts, Pilly Labs’ natural formulations are gaining traction across TikTok rituals, Google search trends, and Reddit supplement stacks — not as prescriptions, but as daily wellness additions for those exploring inflammation support and whole body vitality. 
In a year defined by holistic health trends, anti-inflammatory nutrition stacks, and consumer-led demand for clean-label routines, Pilly Labs is emerging as a go-to gummy supplement brand for wellness seekers prioritizing transparency and convenience. With turmeric, mushroom extracts, and collagen continuing to dominate 2025’s ingredient interest charts, Pilly Labs’ natural formulations are gaining traction across TikTok rituals, Google search trends, and Reddit supplement stacks — not as prescriptions, but as daily wellness additions for those exploring inflammation support and whole body vitality.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers